Présentation de l'entreprise
ImmuCell Corporation, trading under the ticker ICCC, functions as an animal health enterprise dedicated to developing, manufacturing, and selling products designed to enhance the health and productivity of dairy and beef cattle operations both domestically and internationally. The company operates within the Healthcare sector and specifically targets the Biotechnology industry, a classification that underscores its focus on scientific innovation and specialized product development rather than traditional manufacturing or service provision. Currently, the enterprise employs 73 individuals to support its operations across two distinct business segments focused on Scours and Mastitis, alongside the development of oral health solutions like First Defense. With a market capitalization of $57.72M and annual revenue of $27.64M, ImmuCell occupies the position of a small-cap entity within the broader biotechnology landscape. These valuation figures indicate that the company operates with a limited market footprint relative to large-cap peers, suggesting a niche market position where success depends heavily on the adoption of its specific veterinary formulations by cattle producers.
Santé financière
The company reported a revenue of $27.64M for the trailing twelve months, while posting a net income of $-1,040,027 and an EBITDA of $5.18M, a divergence that reveals a significant gap between operational profitability and the bottom line driven by non-operating expenses or taxes. The generation of $998,360 in free cash flow provides the company with a degree of financial flexibility, allowing it to fund operations or invest in research without relying on external capital injections. Profitability metrics show a gross margin of 41.4%, which suggests a healthy pricing power or cost control on core products, yet an operating margin of 9.7% and a profit margin of -3.8% indicate that high overhead costs or other expenses are eroding the bottom line. The balance sheet shows the company holds $3.81M in cash against $13.19M in debt, resulting in a debt-to-equity ratio of 48.77, which characterizes a leveraged balance sheet typical for early-stage biotechnology firms but one that requires careful management of refinancing risks. Short-term liquidity appears robust with a current ratio of 4.26, indicating that the company holds significantly more current assets than current liabilities to meet obligations as they come due. Return metrics display a return on equity of -3.8% and a return on assets of 3.5%, revealing that while the asset base generates a positive return, the negative equity return reflects the company's current unprofitability and the dilution impact of its capital structure on shareholder value.
Évaluation de la valorisation
Valuation multiples for ImmuCell present a mixed picture, with a P/E ratio (TTM) of N/A and a forward P/E of -58.00, the latter implying that earnings are currently negative and the metric cannot be used to assess traditional value until profitability is restored. The price-to-book ratio stands at 2.13, suggesting that the market values the company at more than twice its net asset book value, a premium often associated with intangible assets, proprietary technology, or growth potential that is not captured on the balance sheet. Alternative valuation metrics such as a price-to-sales ratio of 2.09 and an EV/EBITDA of 12.96 provide insight into the company's valuation relative to its revenue generation and earnings before interest, taxes, depreciation, and amortization. The stock's trading range over the last year spans from a 52-week low of $4.52 to a 52-week high of $7.60, placing the current market price within a range that reflects recent volatility but below its yearly peak. The beta of 0.31 indicates that the stock exhibits low volatility relative to the broader market, moving less than half as much as the S&P 500 in typical market conditions, which may appeal to investors seeking lower correlation assets despite the inherent risks of the biotechnology sector.
Growth & Income
Revenue growth for the trailing twelve months declined by 1.6% year-over-year, while earnings growth is marked as N/A due to the negative net income position, meaning earnings are not growing in the traditional sense but rather reflecting ongoing operational challenges. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute profits to shareholders, instead retaining all earnings to fund research, development, and working capital needs. This reinvestment strategy is standard for biotechnology companies that prioritize product pipeline expansion and regulatory approvals over immediate income distribution to shareholders. The overall growth and income profile for ImmuCell Corporation is currently defined by revenue contraction and a lack of dividend income, relying entirely on future product adoption and potential profitability turns to drive shareholder value appreciation.